
Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 D00-D09: In situ neoplasms



Survival

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sD0009E-ICD-10-D00-D09-In-situneoplasms-survival.pdf

Index of figures and tables

| Fig./1b | l. | Page |
|---------|--|------|
| 1a | Relative survival by period of diagnosis (chart) | 3 |
| 1b | Survival by period of diagnosis (table) | 3 |
| 2a | Survival by sex (chart) | 4 |
| 2b | Survival by sex (table) | 4 |
| 3a | Relative survival by age category (chart) | 5 |
| 3b | Survival by age category (table) | 5 |

MCR




Figure 1a. Relative survival of patients with in situ neoplasms by period of diagnosis. Included in the evaluation are 35,749 cases diagnosed between 1988 and 2020.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

| Period of diagnosis | | | | | | | | |
|---------------------|--------|--------|---------|------------|----------|--------|--------|--------|
| | 1988- | 1997 | 1998- | -2006 2007 | | 2015 | 2016+ | |
| | n=2, | 887 | n=7,672 | | n=17,527 | | n=7, | 663 |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 96.7 | 99.9 | 97.4 | 99.7 | 98.1 | 100.0 | 98.0 | 99.8 |
| 2 | 92.7 | 98.9 | 95.1 | 99.6 | 96.2 | 99.9 | 96.3 | 99.9 |
| 3 | 89.6 | 98.5 | 92.5 | 99.1 | 94.3 | 99.8 | 95.2 | 100.5 |
| 4 | 85.7 | 97.1 | 89.8 | 98.4 | 92.2 | 99.4 | 93.0 | 100.1 |
| 5 | 83.0 | 96.7 | 87.3 | 97.8 | 90.2 | 99.0 | 90.9 | 99.7 |
| 6 | 79.3 | 95.1 | 84.8 | 97.1 | 88.2 | 98.7 | | |
| 7 | 76.6 | 94.4 | 82.3 | 96.4 | 86.0 | 97.9 | | |
| 8 | 72.9 | 92.4 | 80.1 | 96.0 | 83.6 | 97.0 | | |
| 9 | 69.9 | 91.0 | 77.4 | 94.8 | 81.4 | 96.2 | | |
| 10 | 66.9 | 89.3 | 74.7 | 93.6 | 79.3 | 95.4 | | |
| Median | 16.5 | | 20.9 | | | / | | |
| | | | | | | | | |

Table 1b. Observed (obs.) and relative (rel.) survival of patients with in situ neoplasms by period of diagnosis for period 1988-2020 (N=35,749).




Figure 2a. Survival of patients with in situ neoplasms by sex. Included in the evaluation are 32,862 cases diagnosed between 1998 and 2020.

| | | Sex | | | |
|--------|--------|--------|--------|--------|--|
| | Ma | ale | Ferr | nale | |
| | n=11 | ,449 | n=21 | ,413 | |
| Years | obs. % | rel. % | obs. % | rel. % | |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | |
| 1 | 96.1 | 99.6 | 98.9 | 100.1 | |
| 2 | 92.6 | 99.4 | 97.8 | 100.1 | |
| 3 | 89.1 | 99.1 | 96.7 | 100.2 | |
| 4 | 85.5 | 98.5 | 95.3 | 99.8 | |
| 5 | 81.6 | 97.6 | 94.0 | 99.7 | |
| 6 | 78.2 | 96.8 | 92.7 | 99.5 | |
| 7 | 74.3 | 95.5 | 91.3 | 99.2 | |
| 8 | 70.7 | 94.2 | 89.9 | 98.7 | |
| 9 | 66.9 | 92.6 | 88.3 | 98.2 | |
| 10 | 63.4 | 91.1 | 86.7 | 97.7 | |
| 11 | 60.2 | 89.9 | 85.2 | 97.3 | |
| 12 | 56.7 | 88.1 | 83.6 | 97.0 | |
| 13 | 53.6 | 86.6 | 81.6 | 96.0 | |
| 14 | 50.5 | 84.8 | 79.7 | 95.3 | |
| 15 | 47.3 | 82.7 | 78.1 | 95.1 | |
| Median | 14.1 | | | | |
| | | | | | |

Table 2b. Observed (obs.) and relative (rel.) survival of patients with in situ neoplasms by sex for period 1998-2020 (N=32,862).




Figure 3a. Relative survival of patients with in situ neoplasms by age category. Included in the evaluation are 32,862 cases diagnosed between 1998 and 2020.

| | | Age category | | | | | | | |
|--|--------|--------------|--------|-----------|--------|--------|--------|---------|--------|
| | | 0-49 | yrs | 50-59 yrs | | 60-69 | 9 yrs | 70+ yrs | |
| | | n=11 | ,219 | n=5, | 186 | n=6, | 680 | n=9 | 777 |
| | Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| | 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| | 1 | 99.9 | 100.0 | 99.5 | 100.0 | 98.6 | 99.8 | 94.4 | 99.9 |
| | 2 | 99.8 | 100.0 | 99.0 | 99.9 | 97.4 | 99.9 | 89.2 | 99.9 |
| | 3 | 99.7 | 99.9 | 98.4 | 99.9 | 96.1 | 99.9 | 84.3 | 100.1 |
| | 4 | 99.6 | 100.0 | 97.7 | 99.7 | 94.3 | 99.5 | 78.7 | 99.4 |
| | 5 | 99.4 | 99.9 | 96.9 | 99.5 | 92.7 | 99.4 | 73.2 | 98.5 |
| | 6 | 99.3 | 99.9 | 96.0 | 99.3 | 91.0 | 99.3 | 68.2 | 98.1 |
| | 7 | 99.1 | 99.8 | 95.2 | 99.2 | 88.8 | 98.7 | 63.0 | 97.2 |
| | 8 | 98.9 | 99.8 | 94.3 | 99.0 | 86.7 | 98.3 | 57.7 | 95.8 |
| | 9 | 98.6 | 99.7 | 93.5 | 99.1 | 84.1 | 97.6 | 52.5 | 94.2 |
| | 10 | 98.5 | 99.7 | 92.5 | 99.0 | 81.7 | 97.1 | 47.5 | 92.5 |
| | Median | | | | | 20.5 | | 9.5 | |

Table 3b. Observed (obs.) and relative (rel.) survival of patients with in situ neoplasms by age category for period 1998-2020 (N=32,862).

Shortcuts

| MCR | Munich Cancer Registry, Germany | | | | | | |
|------|--|---|--|--|--|--|--|
| NCI | National Cancer Institute, USA | | | | | | |
| SEER | Surveillance, Epidemiology, and End Results, USA | | | | | | |
| UICC | Union for International Cancer Control, Geneva | | | | | | |
| | | | | | | | |
| DCO | Death certificate only | Death certificate provides the only notification to the registry. | | | | | |
| NA | Not available | | | | | | |
| NOS | Not otherwise specified | | | | | | |
| OS | Overall/Observed survival | Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause | | | | | |
| RS | Relative survival | Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival | | | | | |
| AS | Assembled survival | Assembled chart of observed, expected, relative survival | | | | | |
| CS | Conditional survival | Survival probability under the condition of surviving a given period of time | | | | | |
| TTP | Time to progression | Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression | | | | | |
| | 1-КМ | 1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator) | | | | | |
| | CI | Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice) | | | | | |
| PPS | Post-progression survival | Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause | | | | | |

Recommended Citation

Munich Cancer Registry. Survival ICD-10 D00-D09: In situ neoplasms [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sD0009E-ICD-10-D00-D09-In-situ-neoplasms-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.